NovaBay [NBY] vs Adagene [ADAG] Detailed Stock Comparison

NovaBay Pharmaceuticals, Inc.

NYSE
Loading...

Adagene Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: NovaBay Pharmaceuticals, Inc. wins in 7 metrics, Adagene Inc. wins in 7 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric NovaBay Pharmaceuticals, Inc. Adagene Inc. Better
P/E Ratio (TTM) 0.04 N/A N/A
Price-to-Book Ratio N/A 4.95 N/A
Debt-to-Equity Ratio -0.03 12.07 Adagene Inc.
PEG Ratio -2.38 -7.10 NovaBay Pharmaceuticals, Inc.
EV/EBITDA -5.95 -7.89 NovaBay Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% -229.56% NovaBay Pharmaceuticals, Inc.
Operating Margin (TTM) 350.10% -74.96% NovaBay Pharmaceuticals, Inc.
EBITDA Margin (TTM) 350.10% N/A N/A
Return on Equity 95.53% -34.39% NovaBay Pharmaceuticals, Inc.
Return on Assets (TTM) -76.11% -16.00% Adagene Inc.
Free Cash Flow (TTM) $-8.43M $-15.67M NovaBay Pharmaceuticals, Inc.
1-Year Return -53.82% 104.64% Adagene Inc.
Price-to-Sales Ratio (TTM) N/A 31.78 N/A
Enterprise Value $45.09M $165.63M Adagene Inc.
EV/Revenue Ratio N/A 21.59 N/A
Revenue per Share (TTM) $0 $0 Adagene Inc.
Earnings per Share (Diluted) $-28.50 $-0.37 Adagene Inc.
Beta (Stock Volatility) 0.16 0.59 NovaBay Pharmaceuticals, Inc.
Short % of Float 9.79% 0.19% Adagene Inc.

NovaBay Pharmaceuticals, Inc. vs Adagene Inc. Stock Performance Analysis

Loading Price Chart...

NBY
ADAG

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
NovaBay Pharmaceuticals, Inc.0.87%-17.14%-11.45%-21.62%-78.11%-96.05%
Adagene Inc.2.06%-13.50%-5.46%16.50%67.96%88.04%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
NovaBay Pharmaceuticals, Inc.-53.82%-98.79%-99.97%-99.99%-100.00%-100.00%
Adagene Inc.104.64%198.50%-71.19%-85.65%-85.65%-85.65%

Performance & Financial Health Analysis: NovaBay Pharmaceuticals, Inc. vs Adagene Inc.

MetricNBYADAG
Market Information
Market Cap i$34.35M$243.81M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i186,830283,167
90 Day Avg. Volume i486,346305,132
Last Close$1.16$3.46
52 Week Range$1.08 - $99.75$1.30 - $4.75
% from 52W High-98.84%-27.16%
All-Time High$130,156.25 (Oct 22, 2007)$31.83 (Feb 08, 2021)
% from All-Time High-100.00%-89.13%
Growth Metrics
Quarterly Revenue Growth-2.00%73.33%
Quarterly Earnings Growth-1.23%N/A
Financial Health
Profit Margin (TTM) i0.00%-2.30%
Operating Margin (TTM) i3.50%-0.75%
Return on Equity (TTM) i0.96%-0.34%
Debt to Equity (MRQ) i-0.0312.07
Cash & Liquidity
Book Value per Share (MRQ)$-0.92$0.75
Cash per Share (MRQ)$0.30$1.28
Operating Cash Flow (TTM) i$2.70M$-15,657,450
Levered Free Cash Flow (TTM) i$-4,935,750$-10,250,600
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i$0.00N/A

Valuation & Enterprise Metrics Analysis: NovaBay Pharmaceuticals, Inc. vs Adagene Inc.

MetricNBY (Apr 24, 2026)ADAG (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i0.04N/A
Forward P/E i-2.38-7.10
PEG Ratio i-2.38-7.10
Price to Sales (TTM) iN/A31.78
Price to Book (MRQ) iN/A4.95
Market Capitalization
Market Capitalization i$34.35M$243.81M
Enterprise Value i$45.09M$165.63M
Enterprise Value Metrics
Enterprise to Revenue iN/A21.59
Enterprise to EBITDA i-5.95-7.89
Risk & Other Metrics
Beta i0.160.59
Book Value per Share (MRQ) i$-0.92$0.75

Financial Statements Comparison: NovaBay Pharmaceuticals, Inc. vs Adagene Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNBY (2025)ADAG (2025)
Revenue/Sales i07.67M
Cost of Goods Sold iN/AN/A
COGS % of Revenue i-0.0%
Gross Profit iN/AN/A
Gross Margin i-0.0%
Research & Development iN/A22.03M
Operating Income (EBIT) i-7.59M-21.44M
Operating Margin i--279.5%
EBITDA i-7.47M-18.22M
EBITDA Margin i--237.5%
Pre-Tax Income i-33.22M-17.91M
Pre-Tax Income % of Revenue i--233.4%
Income Tax iN/A-297,860
Income Tax % of Revenue i--3.9%
Net Income (Profit) i-22.14M-17.61M
Profit Margin i--229.6%

Balance Sheet & Liquidity Metrics

MetricNBY (2025)ADAG (2025)
Cash & Equivalents i7.96M74.52M
Total Current Assets i8.68M77.38M
Total Current Assets % of Revenue i-1,008.7%
Total Current Liabilities i1.14M25.17M
Total Current Liabilities % of Revenue i-328.2%
Long-Term Debt i287,0001.19M
Long-Term Debt % of Revenue i-15.5%
Total Shareholders Equity i-23.18M35.35M
Retained Earnings i-210.42M-328.79M
Retained Earnings % of Revenue i--4,286.1%
Property, Plant & Equipment i01.82M

Cash Flow Statement Comparison

MetricNBY (2025)ADAG (2025)
Operating Cash Flow i-33.33M-11.52M
Operating Cash Flow % of Revenue i--150.1%
Capital Expenditures iN/A-15,653
Free Cash Flow i-8.43M-15.67M
FCF Margin i--204.3%
Debt Repayment i-2.50M-17.88M
Common Stock Repurchase i-175,000N/A

Short Interest & Institutional Ownership Analysis

MetricNBYADAG
Shares Short i333,12071,244
Short Ratio i0.690.34
Short % of Float i9.79%0.19%
Shares Outstanding i25.22M59.23M
Float Shares i2.62M41.42M
% Held by Insiders i90.14%11.07%
% Held by Institutions i5.34%20.50%
% Held by Public i4.52%68.43%

Dividend Analysis & Yield Comparison: NovaBay Pharmaceuticals, Inc. vs Adagene Inc.

MetricNBYADAG
Last 12-Month Dividend i$0.00N/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i$0.00N/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i$0.00N/A
Ex-Dividend DateN/AN/A